Michael J. Blankinship

Michael Blankinship practices at Medpark Specialized Surgery in Fargo, North Dakota.

Michael Blankinship's NPI, 1780826867, was assigned on April 3, 2009. Michael Blankinship graduated from University Of Michigan Medical School in 2005. Michael Blankinship's North Dakota license number on file is 12697.

Michael Blankinship's primary practice is Medpark Specialized Surgery, at 4450 31st Avenue S, STE 201, Fargo, ND 58104. The practice phone is (701) 951-2020.

Michael Blankinship's primary practice is Medpark Specialized Surgery in Fargo, North Dakota. Michael Blankinship is also affiliated with Sanford Broadway Medical Center. The medical group on file is ima Healthcare. Dmand AI also links Michael Blankinship to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael Blankinship practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Michael Blankinship's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Michael Blankinship is board certified in dermatology by the American Board of Dermatology. Dmand AI has Michael Blankinship's licenses on file in 2 states: North Dakota and Michigan.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, contact dermatitis, corns and calluses, hives, itchy rashes and joint cyst among the conditions Michael Blankinship treats.

CMS data shows 2,812 Medicare services from Michael Blankinship across 23 procedure codes in 2024, for 686 Medicare patients. Medicare paid $111,846 for them. Every service was in an office.

CMS counts 686 Medicare patients who saw Michael Blankinship in 2024. The largest group is 65 to 74, with 381 patients. 72% of them have high cholesterol, and 68% have high blood pressure. 4% are also on Medicaid. Their average risk score is 0.99, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Michael Blankinship's median patient age at 64, with 58% women.

In 2024, Michael Blankinship wrote 1,459 Medicare Part D claims for 413 patients. 90% of them were for generic drugs. CMS names the drug for 1,289 of them, across 30 drugs with 11 or more claims each, at $651,309 in total drug cost. In 2023, CMS named 1,094 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 0 out of 100 for Michael Blankinship for performance year 2024, reported individually. Michael Blankinship accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 62 procedures of melanoma (skin cancer) excision by Michael Blankinship, more than 89% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 13 papers to Michael Blankinship, published from 2004 to 2009. 2007 was the busiest year, with 2. The most frequent topics are Genetic Vectors, Muscle, Skeletal and Dependovirus. Michael Blankinship has published most often in Mol Ther. Michael Blankinship's most frequent co-authors are Eric J. Devaney, MD and Elina Minami, MD.

CMS Open Payments shows 361 general payments to Michael Blankinship from 21 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 84% of the total. Eli Lilly and Company paid the most, $101,222. It also lists 2 research payments totaling $4,820 from 2024 to 2025, naming 1 clinical trial.

Michael Blankinship graduated from University Of Michigan Medical School in 2005.

Michael Blankinship is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.